Dysregulation of KIF14 regulates the cell cycle and predicts poor prognosis in cervical cancer: a study based on integrated approaches

Cervical cancer (CC) is the most common malignant tumor in females. Although persistent high-risk human papillomavirus (HPV) infection is a leading factor that causes CC, few women with HPV infection develop CC. Therefore, many mechanisms remain to be explored, such as aberrant expression of oncogenes and tumor suppressor genes. To identify promising prognostic factors and interpret the relevant mechanisms of CC, the RNA sequencing profile of CC was downloaded from the Cancer Genome Atlas and the Gene Expression Omnibus databases. The GSE63514 dataset was analyzed, and differentially expressed genes (DEGs) were obtained by weighted coexpression network analysis and the edgeR package in R. Fifty-three shared genes were mainly enriched in nuclear chromosome segregation and DNA replication signaling pathways. Through a protein-protein interaction network and prognosis analysis, the kinesin family member 14 (KIF14) hub gene was extracted from the set of 53 shared genes, which was overexpressed and associated with poor overall survival (OS) and disease-free survival (DFS) of CC patients. Mechanistically, gene set enrichment analysis showed that KIF14 was mainly enriched in the glycolysis/gluconeogenesis signaling pathway and DNA replication signaling pathway, especially in the cell cycle signaling pathway. RT-PCR and the Human Protein Atlas database confirmed that these genes were significantly increased in CC samples. Therefore, our findings indicated the biological function of KIF14 in cervical cancer and provided new ideas for CC diagnosis and therapies.

Inmunología del cáncer II: bases moleculares y celulares de la carcinogénesis / Cancer immunology II: molecular and cellular bases of carcinogenesis

El desarrollo tecnológico de las últimas dos décadas aplicado a la investigación científica preclínica y clínica, ha permitido expandir significativamente los conocimientos acerca de la biología de las células neoplásicas. La caracterización de las alteraciones genéticas y epigenéticas que sustentan la carcinogénesis, la subclasificación molecular de los tumores, la comprensión de las interacciones que establecen las células neoplásicas con otras poblaciones celulares en el microambiente tumoral, así como la descripción de las bases moleculares que permiten explicar la influencia de factores como ejercicio, la dieta y la composición de la microbiota en la progresión tumoral, han contribuido a sustentar la relevancia del tratamiento de precisión en cáncer. Este trabajo revisa los llamados sellos del cáncer y sus cualidades habilitantes, o sea, aquellas propiedades inherentes a las células neoplásicas que le permiten evadir los mecanismos intrínsecos y extrínsecos que controlan la carcinogénesis. Con este trabajo damos continuidad a la serie sobre inmunología del cáncer que iniciamos con la presentación de las bases moleculares y celulares de la respuesta inmune antitumoral y que, finalmente, abordará la manipulación de la relación entre el sistema inmune y las neoplasias como estrategia de terapia para el cáncer.

Technological advances applied to preclinical and clinical scientific research have significantly enabled the broadening of knowledge regarding neoplastic cells biology in the last two decades. The characterization of genetic and epigenetic alterations which are involved in carcinogenesis; the molecular subclassification of tumors; the understanding of normal and neoplastic cells interactions in the tumor microenvironment; and the description of molecular bases that explain the influence of factors such as exercise, diet and microbiota composition on cancer progression have contributed to support the importance of precision medicine in cancer. The present research reviews the so-called "hallmarks of cancer" and their "enabling characteristics", i.e. those properties inherent to cancer cells that allow to evade intrinsic and extrinsic mechanisms of carcinogenesis control. This paper is a follow-up review of studies on cancer immunology that started with the presentation of the molecular and cellular bases of the anti-tumoral immune response, and will eventually focus on the manipulation of the relationship between the immune system and malignancies as a cancer treatment strategy.

Expressão e caracterização da glicoproteína D do HSV-1 geneticamente fusionada às oncoproteínas E6 e E7 do HPV-16 e HPV-18 (gDE7E6) em células de mamífero / Expression and characterization of the genetically fused HSV-1 glycoprotein D to E6 and E7 oncoproteins HPV-16 e HPV-18 (gDE7E6) in mammalian cells

O câncer cervical é um dos tipos de câncer mais comuns entre as mulheres, e a infecção persistente pelos HPV-16 e HPV-18 é responsável por 70% dos casos. As vacinas profiláticas disponíveis possuem alta eficácia na prevenção da infecção pelos tipos mais prevalentes de HPV. No entanto, este tipo de abordagem não beneficia mulheres que já apresentam lesões precursoras ou tumores cervicais avançados, e a busca por abordagens terapêuticas para esse tipo de câncer é considerada uma necessidade. A qualidade do antígeno representa um aspecto fundamental para o sucesso de vacinas terapêuticas baseadas em proteínas recombinantes. Neste sentido, os sistemas de expressão em células eucarióticas, como leveduras e células de mamíferos são considerados adequados para a produção de proteínas com aplicação biotecnológica. O objetivo principal deste trabalho contemplou a expressão das proteínas de fusão gDE7E6 do HPV-16 e do HPV-18 e a oncoproteína E7 do HPV-16 em células da levedura Pichia pastoris e expressão da gDE7E6 do HPV-16 e do HPV-18 em células de mamífero HEK293T e CHODG-44 para obtenção de antígenos purificados com futura aplicação em vacinas terapêuticas contra tumores associados ao HPV-16 e HPV-18. Os genes que codificam as proteínas gDE7E6 dos HPV-16 e HPV-18 e da E7 do HPV-16 foram clonados no vetor pPIC9K, os quais foram linearizados por digestão enzimática e utilizados na transformação da P. pastoris. A expressão das proteínas foi analisada nos tempos de 24, 48, 72 e 96 horas, no entanto, não foi observada a produção das proteínas no sobrenadante e nem no lisado celular. Diante desta constatação, iniciamos a expressão das proteínas gDE7E6 do HPV-16 e gDE7E6 do HPV-18 em células de mamíferos HEK293T e CHODG-44. As sequências genéticas das proteínas gDE7E6 do HPV-16 e do HPV-18 foram clonadas no vetor de expressão pNU1 e analisadas por digestão enzimática. Análises de SDS-PAGE e western blot demonstraram a expressão das proteínas gDE7E6 do HPV-16 e do HPV-18 em até 96 horas em células HEK293T. Em paralelo, realizamos a transfecção estável dos plasmídeos contendo as sequencias da gDE7E6 do HPV-16 e gDE7E6 do HPV-18 em células CHO-DG44. Com o intuito de aumentar a expressão das proteínas de interesse na população mista de CHODG-44, realizamos amplificação genômica com metotrexato (MTX), sendo possível observar aumento da expressão das proteínas, conforme aumento gradativo nas concentrações de MTX. Posteriormente, foram feitas tentativas para isolar um clone produtor das proteínas gDE7E6 HPV-16 e HPV-18, através de clonagem por diluição limitante e sistema automatizado, sendo possível isolar um clone para cada construção através de matriz semisólida, confirmado por western blot e citometria de fluxo. Apesar de demonstrar a expressão das proteínas de interesse em sistema de expressão baseado em células de mamífero, o rendimento obtido após a purificação por afinidade ao níquel foi extremamente baixo, o que dificulta a obtenção dos antígenos para fins vacinais

Cervical cancer is one of the most common cancers among women, and persistent infection with HPV-16 and HPV-18 accounts for 70% of the cases. Available prophylactic vaccines are highly effective in preventing infection by the most prevalent types of HPV. However, this type of approach does not benefit women who already have precursor lesions or advanced cervical tumors, and the search for therapeutic approaches to this type of cancer is considered a necessity. Antigen quality represents a key aspect for the success of therapeutic vaccines based on recombinant proteins. In this sense, expression systems based in eukaryotic cells such as yeast and mammalian cells are considered suitable for the production of proteins with biotechnological applications. The main objective of this work was to express the gDE7E6 fusion proteins HPV-16 and HPV-18 and the E7 oncoprotein HPV-16 in Pichia pastoris and expression of gDE7E6 HPV-16 and HPV-18 in mammalian cells HEK293T and CHODG-44 to obtain purified antigens with future applications in therapeutic vaccines against HPV-16 and HPV-18 associated tumors. The genes encoding the gDE7E6 proteins HPV-16 and HPV-18 and E7 HPV-16 were cloned into the pPIC9K vector, which were linearized by enzymatic digestion and used in the transformation of P. pastoris. Expression of the proteins was analyzed at 24, 48, 72 and 96 hours, however, the production of the proteins in the supernatant and in the cell lysate was not observed. In light of this finding, we initiated the expression of gDE7E6 proteins HPV-16 and HPV-18 in mammalian cells HEK293T and CHODG-44. The genetic sequences of gDE7E6 proteins HPV-16 and HPV-18 were cloned into the pNU1 expression vector and analyzed by enzymatic digestion. SDSPAGE and western blot analyzes demonstrated expression of gDE7E6 proteins HPV-16 and HPV-18 within 96 hours in HEK293T cells. In parallel, we performed stable transfection of plasmids containing gDE7E6 HPV-16 and HPV-18 sequences into CHODG44 cells. In order to increase the expression of the proteins in the mixed population of CHODG-44, we performed genomic amplification with methotrexate (MTX), and it was possible to observe an increase in protein expression, as a gradual increase in MTX concentrations. Therefore, attempts were made to isolate a clone producing gDE7E6 proteins HPV-16 and HPV-18 by limiting dilution and automated system, being possible to isolate one clone for each construct through a semisolid matrix, confirmed by western blot and flow cytometry. Despite observing protein expression in mammalian cell-based expression system, the yield obtained after nickel affinity purification was extremely low, which makes it difficult to obtain the antigens for vaccine purposes

Detección de ARNm de oncoproteínas E6/E7 del Virus del Papiloma Humano en cáncer de cuello uterino / Detection of Human Papillomavirus E6/E7 mRNA in cervical cancer / Detecção de RNAm de oncoproteínas E6/E7 do Vírus do Papiloma Humano em câncer de colo de útero

La infección de transmisión sexual por el Virus del Papiloma Humano (VPH) es una de las más comunes en el mundo. Los VPH se clasifican en bajo riesgo y alto riesgo. Los VPH de bajo riesgo son los causantes de lesiones benignas como verrugas genitales y condilomas acuminados, mientras que los VPH de alto riesgo pueden originar la transformación maligna de las células del epitelio cervical por la acción de las oncoproteínas E6 y E7, lo que puede dar origen al cáncer de cuello uterino. La detección de los niveles de ARN mensajero (ARNm) de E6 y E7 de VPH en las células del epitelio cervical está siendo evaluada como un marcador predictivo del cáncer de cuello uterino como alternativa a las técnicas de detección del ADN de VPH. En este artículo se realizó una revisión crítica acerca de la relación existente entre la detección de la expresión de ARNm de E6 y E7 del virus del papiloma humano y el cáncer de cuello uterino. Además, se revisaron las técnicas aprobadas actualmente por la FDA (Food and Drug Administration) para la detección de ARNm de las oncoproteínas E6 y E7 de VPH y el estado del arte del VPH en Colombia.

The sexually transmitted infection by the Human Papillomavirus (HPV) is one of the most common in the world. Human papillomaviruses are classified as low risk and high risk. Low-risk HPVs are the cause of benign lesions such as genital warts and condylomata acuminata, while high-risk HPV types can cause malignant transformation of cervical epithelial cells by the action of oncoproteins E6 and E7, which could result in the development of cervical cancer. The detection of levels of HPV E6 and E7 mRNA (messenger RNA) in cervical epithelial cells is being evaluated as a predictive marker of cervical cancer as an alternative to HPV DNA detection techniques. In this article, a critical review was made about the relationship between the detection of E6 and E7 mRNA expression of human papillomavirus and cervical cancer. Furthermore, the techniques currently approved by the Food and Drug Administration (FDA) for the detection of mRNA from the HPV E6 and E7 oncoproteins and the state of the art of HPV in Colombia were reviewed.

A infecção sexualmente transmissível pelo Vírus do Papiloma Humano (HPV) é uma das mais comuns no mundo. Os HPV são classificados em tipos de baixo e de alto risco. Os HPV de baixo risco são a causa de lesões benignas, tais como verrugas genitais e condilomas acuminados, enquanto que os HPV de alto risco podem causar a transformação maligna das células do epitélio cervical pela ação das oncoproteínas E6 e E7, o que pode dar origem ao câncer de colo de útero. A detecção dos níveis de RNA Mensageiro (RNAm) E6 e E7 de HPV nas células do epitélio cervical está sendo avaliada como marcador preditivo do câncer de colo de útero como alternativa às técnicas de detecção de DNA do HPV. Neste artigo, foi realizada uma revisão crítica sobre a relação entre a detecção da expressão de RNAm E6 e E7 do vírus do papiloma humano e o câncer do colo de útero. Do mesmo modo, foram revisadas as técnicas aprovadas pela FDA (Food and Drug Administration) para detecção de ARNm das oncoproteínas E6 e E7 de HPV e o estado da arte do HPV na Colômbia.

Evaluation of therapeutic potency of human papillomavirus-16 E7 DNA vaccine alone and with interleukin-18 as a genetic adjuvant / Avaliação da potência terapêutica da vacina de DNA do papilomavírus humano-16 E7 isolada e com interleucina-18 como adjuvante genético

AIMS: Despite the existence of effective preventive vaccines for human papillomavirus (HPV), therapeutic vaccines that trigger cell-mediated immune responses are required to treat established infections and malignancies. The aim of this study was to evaluate the therapeutic potency of HPV-16 E7 deoxyribonucleic acid (DNA) vaccine alone and with interleukin (IL)-18. METHODS: In vitro expressions of IL-18 were performed on human embryonic kidney 293 cells and confirmed it by Western blotting methods. DNA vaccine was available from a previous study. A total of 45 female C57BL/6 mice divided into five groups (DNA vaccine, DNA vaccine adjuvanted with IL-18, pcDNA3.1, and phosphate buffer saline) were inoculated with murine tissue culture-1 cell line of HPV related carcinoma, expressing HPV-16 E6/E7 antigens. They were then immunized subcutaneously twice at a seven-day interval. The antitumor and antigen specific-cellular immunity were assessed by lymphocyte proliferation (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide: MTT) assay, lactate dehydrogenase release assay, IL-4 assay and interferon-gamma (IFN-γ) assay. Tumor size was followed for 62 days. RESULTS: MTT assay, which measures the lymphocyte proliferation in response to the specific antigen, increased in the co-administration and the DNA vaccine groups as compared to control and genetic adjuvant groups (p<0.001). The mice immunized with the co-administration generated significantly more IFN-γ and IL-4 than other immunized mice (p<0.001). Reduction of the tumor size in the co-administration and the DNA vaccine groups was significantly more pronounced than in the control and genetic adjuvant groups (p<0.001), but no statistically significant difference between DNA vaccine and co-administration groups (p=0.15) occurred. CONCLUSIONS: IL-18 as a genetic adjuvant and E7 DNA vaccine alone enhanced immune responses in mouse model systems against cervical cancer. However, using of IL-18 as a genetic adjuvant with E7 DNA vaccine had no significant synergistic effect on the immune responses in vivo.

OBJETIVOS: Apesar da existência de vacinas preventivas eficazes contra o papilomavírus humano (HPV), são necessárias vacinas terapêuticas que desencadeiem respostas imunes mediadas por células para tratar infecções e malignidades estabelecidas. O objetivo deste estudo foi avaliar a potência terapêutica da vacina de ácido desoxirribonucleico (DNA) HPV-16 E7 isolada e com interleucina (IL)-18. MÉTODOS: Expressões in vitro de IL-18 foram realizadas em células renais embrionárias humanas 293 e confirmadas por Western blotting. A vacina de DNA foi disponibilizada em um estudo anterior. Um total de 45 camundongos fêmeas C57BL/6 divididos em cinco grupos (vacina de DNA, vacina de DNA adjuvada com IL-18, pcDNA3.1 e solução salina tamponada com fosfato) e foram inoculados com linhagem murina-1 de carcinoma relacionado ao HPV, expressando antígenos E6 / E7 do HPV-16. Os animais foram então imunizados por via subcutânea duas vezes no intervalo de sete dias. A imunidade antitumoral e antígeno-celular específica foi avaliada pela proliferação de linfócitos (ensaio de brometo de 3- [4,5-dimetiltiazol-2-il] -2,5-difeniltetrazólio: MTT), ensaio de liberação de lactato desidrogenase, ensaio de IL-4 e ensaio de interferon-gama [IFN-γ]. O tamanho do tumor foi seguido por 62 dias. RESULTADOS: O ensaio MTT, que mede a proliferação de linfócitos em resposta ao antígeno específico, aumentou nos grupos de coadministração e de vacina de DNA em comparação aos grupos controle e adjuvante genético (p <0,001). Os camundongos imunizados com a coadministração geraram significativamente mais IFN-γ e IL-4 do que os outros camundongos imunizados (p<0,001). A redução do tamanho do tumor nos grupos de coadministração e de vacina de DNA foi significativamente mais acentuada do que nos grupos controle e adjuvante genético (p<0,001), mas não houve nenhuma diferença estatisticamente significativa entre os grupos vacina de DNA e coadministração (p=0,15). CONCLUSÕES: A IL-18 como adjuvante genético e a vacina de DNA E7 aumentaram as respostas imunes em sistemas modelo de camundongos contra o câncer cervical. No entanto, o uso de IL-18 como adjuvante genético com a vacina de DNA E7 não teve efeito sinérgico significativo nas respostas imunes in vivo.

MAFB mediates the therapeutic effect of sleeve gastrectomy for obese diabetes mellitus by activation of FXR expression

Farnesoid X receptor (FXR) and related pathways are involved in the therapeutic effect of sleeve gastrectomy for overweight or obese patients with diabetes mellitus. This study aimed to investigate the mechanism of FXR expression regulation during the surgical treatment of obese diabetes mellitus by sleeve gastrectomy. Diabetic rats were established by combined streptozotocin and high-fat diet induction. Data collection included body weight, chemical indexes of glucose and lipid metabolism, liver function, and the expression levels of musculoaponeurotic fibrosarcoma oncogene family B (MAFB), FXR, and related genes induced by sleeve gastrectomy. Chang liver cells overexpressing MAFB gene were established to confirm the expression of related genes. The binding and activation of FXR gene by MAFB were tested by Chip and luciferase reporter gene assays. Vertical sleeve gastrectomy induced significant weight loss and decreased blood glucose and lipids in diabetic rat livers, as well as decreased lipid deposition and recovered lipid function. The expression of MAFB, FXR, and FXR-regulated genes in diabetic rat livers were also restored by sleeve gastrectomy. Overexpression of MAFB in Chang liver cells led to FXR gene expression activation and the alteration of multiple FXR-regulated genes. Chip assay showed that MAFB could directly bind with FXR promoter, and the activation of FXR expression was confirmed by luciferase reporter gene analysis. The therapeutic effect of sleeve gastrectomy for overweight or obese patients with diabetes mellitus was mediated by activation of FXR expression through the binding of MAFB transcription factor.

Genotipificación, niveles de expresión y estado físico del virus del papiloma humano en pacientes colombianos con cáncer de células escamosas en la cavidad oral / Genotyping, levels of expression and physical status of human papilloma virus in oropharyngeal squamous cell carcinoma among Colombian patients

Introducción. Uno de los factores de riesgo del carcinoma de células escamosas en la cavidad oral es la infección por el virus del papiloma humano (HPV), cuyas prevalencias dependen de la región geográfica. Objetivo. Identificar los tipos del virus del papiloma humano más frecuentes en el cáncer de la cavidad bucal, sus niveles de expresión y el estado físico del genoma viral. Materiales y métodos. Se seleccionaron 46 pacientes que asistían a los servicios de cirugía de cabeza y cuello en Bogotá, Manizales y Bucaramanga. El examen histopatológico de las muestras incluidas en el estudio demostró la presencia de carcinoma de células escamosas en la cavidad oral en todas ellas. Se extrajo el ADN para genotipificar el virus y determinar el estado físico de su genoma, y el ARN para determinar los transcritos virales mediante reacción en cadena de la polimerasa en tiempo real. Resultados. La prevalencia del virus del papiloma humano en los tumores fue de 21,74% (n=10) y el tipo viral más frecuente fue el HPV-16 (nueve casos). La expresión viral del HPV-16 fue baja (una de 11 copias) y el estado físico predominante fue el mixto (ocho casos), con prevalencia de la disrupción en el sitio de unión de E1 y E2 (2525 a 3720 nucleótidos). Conclusión. En los pacientes con carcinoma de cavidad oral incluidos en este trabajo, la frecuencia del virus del papiloma humano fue relativamente baja (21,7 %) y el tipo viral más frecuente fue el HPV-16, el cual se encontró en forma mixta y con baja expresión de E7 , lo cual puede ser indicativo de un mal pronóstico para el paciente.

Introduction: One of the risk factors for squamous cell oropharyngeal carcinoma is infection with the human papilloma virus (HPV), with prevalences that vary depending on the geographical region. Objective: To identify the most frequent HPV viral types in oropharyngeal cancer, the levels of expression and the physical condition of the viral genome. Materials and methods: Forty-six patients were included in the study from among those attending head and neck surgical services in the cities of Bogotá, Manizales and Bucaramanga. In the histopathological report all study samples were characterized as oropharyngeal squamous cell carcinoma. DNA extraction was subsequently performed for HPV genotyping and to determine the physical state of the viral genome, as well as RNA to determine viral transcripts using real-time PCR. Results: HPV prevalence in tumors was 21.74% (n=10) and the most common viral type was HPV-16 (nine cases). Viral expression for HPV-16 was low (one of 11 copies) and the predominant physical state of the virus was mixed (eight cases), with disruption observed at the E1 - E2 binding site (2525 - 3720 nucleotides). Conclusion: The prevalence of HPV associated with oropharyngeal carcinoma among the Colombian study population was 21.7%, which is relatively low. The most frequent viral type was HPV-16, found in a mixed form and with low expression of E7 , possibly indicating a poor prognosis for these patients.

High Risk HPV E6/E7 Oncoprotein Expression in Women with High Grade Squamous Intraepithelial Lesion / Expressão de oncoproteinas E6/e7 do HPV de alto risco em Mulheres com Lesão Intraepitelial Escamosa de alto grau

Purpose To correlate the expression of high-risk HPV E6 mRNA with pap smear, colposcopy, and biopsy results in women with high grade squamous intraepithelial lesion (HSIL). Methods A cross-sectional study was performed on women referred for primary care services after cytological diagnosis of HSIL. We evaluated the expression of E6/E7 mRNA of HPV types 16,18,31,33, and 45 and correlated the results with those of Pap smear, colposcopy, and biopsy. For amplification/detection of mRNA E6 / E7 we used NucliSENSEasyQ kit to detect HPV mRNA by polymerase chain reaction with primers/ probes for HPV types 16, 18, 31, 33, and 45. Results Out of 128 valid tests, the results of 30 (23.4%) tests were negative and 98 (70%) tests were positive. Only one type of HPV was detected in 87.7% of the E6/E7 mRNA positive cases. HPV16 was detected in 61.2% of the cases, followed by HPV33 (26.5%), HPV31 (17.3%), HPV18 (10%), and HPV45 (4.08%). Pap smear tests revealed that the E6/E7 test was positive in 107 (83.8%) women with atypical squamous cells - high grade (ASC-H), HSIL, or higher. The E6/E7 test was positive in 69 (57.5%) specimens presenting negative cytology results. When analyzing the association with colposcopy results, the frequency of positive E6/E7 results increased with the severity of the injury, ranging from 57.1% in women without colposcopy-detected injury to 86.5% in those with higher levels of colposcopy findings. Of the 111 women who underwent biopsy and E6/E7 testing, the E6/E7 test was positive in 84.7% of the women who presented with lesions of cervical intraepithelial neoplasia (CIN) grade 2 or higher. Finally, 41.2% of women with a negative biopsy presented a positive E6/E7 test. Conclusions E6/E7mRNA expression was higher in women with HSIL and CIN grade 2 or higher.

Objetivo Correlacionar a expressão mRNAE6/E7 do HPV de alto risco com os exames de Papanicolau, colposcopia e biópsia em mulheres com lesão intraepitelial escamosa de alto grau (HSIL). Métodos Estudo transversal com mulheres encaminhadas aos serviços de atenção primária com diagnóstico citológico de HSIL. Foi avaliada a expressão do mRNAE6/E7 dos tipos de HPV 16,18,31,33 e 45, correlacionando-se a expressão com os exames de Papanicolau, colposcopia e biópsia. Para a amplificação/detecção demRNA de E6/E7 foi usado o kit NucliSENS EasyQ(r) HPV que detecta mRNA do HPV por meio da reação em cadeia da polimerase com primers/probes HPV dos tipos 16, 18, 31, 33 e 45. Resultados Foram obtidos 128 testes válidos. Destes: 30 (23,4%) foram negativos e 98 (70%) dos testes foram positivos. Foi encontrado apenas um tipo de HPV em 87,7% dos positivos. O HPV16 foi omais encontrado em61,2%, seguido pelos HPV33 (26,5%); HPV31 (17,34%); HPV 18 (10,0%) e HPV (45 4,0%). Quanto ao exame de Papanicolau, o teste E6/E7 foi positivo em 107 (83,8%) das mulheres com ASC-H, HSIL ou superior, enquanto em citologia negativa foi encontrado um resultado positivo em 69 (57,5%) colposcopia. A frequência de teste E6/E7 positivo aumentou com a gravidade da lesão, detectada na colposcopia variando de 57,1% em mulheres sem lesão identificada em colposcopia até 86,5% naqueles com achado de colposcopia de grau maior. Das 111 mulheres que se submeteram a biópsia e o teste E6/E7, o teste foi positivo em 84,7% das que apresentaramlesão igual ou superior a NIC 2 (neoplasia intraepitelial cervical) e 41,2% daqueles com biópsia negativa. Conclusões A expressão de E6, E7 RNAm ocorreu commaior frequência emlesões de alto grau citológica e em casos com biópsias de NIC2 ou maior.

Efeito da infecção por HPV nas vias de sinalização por toll like receptors / Effects of HPV infection on TLR signaling pathway

As oncoproteínas E6 e E7 do Papilomavírus Humano (HPV) estão envolvidas na desregulação do sistema imune inato, provocando alterações na expressão dos receptores do tipo Toll (TLR). Considerando-se a função da via de sinalização iniciada por TLR, haveria uma vantagem para o vírus capaz de manipular a resposta desta via de modo que possa persistir nas células sem ser detectado pelo sistema imune ou ainda modulando essa resposta e criando um ambiente mais propício à manutenção da infecção. No entanto, muitos dos mecanismos que levam à eliminação da infecção ou persistência do HPV ainda são pouco conhecidos. O objetivo principal desse trabalho é investigar o papel das vias de TLR no processo de carcinogênese mediado por HPV. Inicialmente, foi analisada a expressão de genes da via de TLR em linhagens de tumores cervicais e em células expressando as oncoproteínas virais. Foram identificados vários genes diferencialmente expressos entre linhagens de células tumorais e queratinócitos normais, incluindo moléculas adaptadoras da via de TLR e genes associados à via da MAP quinase, ativação de NFkappaB e resposta imune antiviral. Cerca de 90% destes genes foram regulados negativamente. Entre eles, destacamos HMGB1, que apesar de possuir menos RNAm nas células tumorais possui um nível proteico muito maior, além de ter-se mostrado de grande importância para a viabilidade e proliferação das células tumorais, conforme demonstrado através de experimentos de supressão gênica. Em conjunto, os nossos dados indicam que E6 e E7 de HPVs de alto risco inibem proteínas da via de sinalização de TLR

Previous studies have shown that E6 and E7 HPV oncoproteins are involved in innate immune system dysregulation, causing alterations on Toll-like receptors (TLR) expression. Considering TLR pathway function, it would be advantageous for a virus to manipulate the response of this pathway so it can persist in cells without being detected by the immune system or to modulate this response to create a better environment for persistence of infection. However, many of the mechanisms leading to HPV infection clearance or persistence are still unknown and matter of active investigation. We analyzed in cervical cancer cell lines expression of genes from TLR pathway; several were differentially expressed between tumor cells lines and normal keratinocytes, including TLR adaptors molecules and genes associated with MAP kinase pathway, NFkappaB activation and antiviral immune response. About 90% of these genes were down regulated. Among them, we selected HMGB1 for further characterization due to its interference with tumor cell viability and proliferation. Altogether, our data indicate that high risk HPV E6 and E7 can inhibit TLR signaling pathway

Papilomavírus humano: biologia viral e carcinogênese / Papillomavirus human: viral biology and carcinogenesis

O Papilomavírus humano (HPV) exerce um papel central na carcinogênese do colo uterino. Os mecanismos utilizados pelos HPVs de alto risco para influenciar o ciclo de divisão celular, levando-o à sua desregulação e, consequentemente, para a progressão de lesões, incluem fatores inerentes ao vírus e à sua inter-relação com a célula hospedeira. Tais interferências no metabolismo celular poderão causar modificações morfológicas e funcionais, promovendo o aparecimento de neoplasias. Compreendendo a importância do conhecimento dos processos biológicos e moleculares utilizados pelo HPV na carcinogênese para o diagnóstico precoce e na avaliação prognóstica da doença, o objetivo deste trabalho foi buscar na literatura científica a relação da biologia viral do HPV com o desenvolvimento do câncer de colo útero e novas descobertas.(AU)

The Human papillomavirus (HPV) plays a central role in carcinogenesis of the cervix. The mechanisms used by high-risk HPVs to influence the cell division cycle taking it to its deregulation and consequently for progression of lesions include factors related to the virus and its interrelationship with the host cell. Changes in cellular metabolism can cause morphological and functional changes, promoting the appearance of tumors. Understanding the importance of knowledge of the biological and molecular processes used by HPV in carcinogenesis for early diagnosis and prognostic evaluation of the disease, the objective was to search the scientific literature regarding the HPV?s viral biology to the development of cervical cancer and new discoveries.(AU)

Technologies of birth and models of midwifery care / Tecnologias no parto e modelos de cuidado obstétrico / Tecnologías en el parto y modelos de cuidado obstétrico

This article is based on a study of a reform in the organisation of maternity services in the United Kingdom, which aimed towards developing a more woman-centred model of care. After decades of fragmentation and depersonalisation of care, associated with the shift of birth to a hospital setting, pressure by midwives and mothers prompted government review and a relatively radical turnaround in policy. However, the emergent model of care has been profoundly influenced by concepts and technologies of monitoring. The use of such technologies as ultrasound scans, electronic foetal monitoring and oxytocic augmentation of labour, generally supported by epidural anaesthesia for pain relief, have accompanied the development of a particular ecological model of birth – often called active management –, which is oriented towards the idea of an obstetric norm. Drawing on analysis of women’s narrative accounts of labour and birth, this article discusses the impact on women’s embodiment in birth, and the sources of information they use about the status of their own bodies, their labour and that of the child. It also illustrates how the impact on women’s experiences of birth may be mediated by a relational model of support, through the provision of caseload midwifery care.

Este artigo baseia-se em um estudo sobre a reforma na organização dos serviços de maternidade no Reino Unido, que teve como objetivo desenvolver um modelo mais centrado na mulher. Após décadas de fragmentação e despersonalização da assistência, associadas à ascensão do hospital como lugar de parir, a pressão de parteiras e mães obrigou o governo a uma revisão e mudança relativamente radical desta política. No entanto, o modelo emergente de cuidados tem sido profundamente influenciado pelos conceitos e tecnologias de monitoramento. O uso de tecnologias como ultra-sonografia, monitoramento eletrônico fetal e aceleração do parto com ocitocina, geralmente acompanhada de anestesia peridural para alívio da dor, tem promovido o desenvolvimento de um modelo ecológico específico de nascimento – muitas vezes chamado de manejo ativo –, orientado pela idéia de uma norma obstétrica. Com base na análise da narrativa das mulheres, este artigo discute o impacto do modelo assistencial no posicionamento das mulheres frente ao parto e as fontes de informação sobre seus corpos, seus partos e o nascimento da criança que elas utilizam. Ilustra, também, como o impacto nas experiências de parto das mulheres pode ser mediado por um modelo relacional de apoio, mediante a prestação de cuidados de obstetrícia no modelo caseload.
.

Este artículo se basa en un estudio sobre la reforma de la organización de los servicios de maternidad en el Reino Unido, que tubo como objetivo desarrollar un modelo más centrado en la mujer. Después de décadas de fragmentación y despersonalización de la atención, asociada con la ascensión del hospital como el lugar de parir, la presión de parteras y madres obligó al gobierno a revisar y hacer un cambio relativamente radical de esta política. Sin embargo, el modelo emergente de atención es profundamente influenciado por los conceptos y las tecnologías de monitoreo. El uso de tecnologías como ecografía, monitorización electrónica fetal y aceleración del parto con oxitocina, por lo general acompañada de anestesia epidural para el alivio del dolor, ha promovido el desarrollo de un modelo ecológico específico de nacimiento – a menudo llamado la manejo de activo –, orientado la idea de una norma obstétrica. Con base en los relatos de las mujeres, este artículo analiza el impacto del modelo de atención en el posicionamiento de las mujeres frente al parto y las fuentes de información acerca de sus cuerpos, sus partos y el nacimiento del niño que ellas utilizan. También ilustra cómo el impacto de las experiencias de parto de las mujeres puede ser mediado por un modelo relacional de apoyo, a través de la prestación de cuidados de partería en el modelo caseload.
.

The effect of 6% Hydroxyethyl starch vs. Ringer's lactate on acute kidney injury after renal ischemia in rats

PURPOSE: To compare fluid replacement therapy with Hydroxyethyl starch 6% (HES) versus Ringer's lactate (RL) in a rodent model of non-septic renal ischemia. METHODS: Forty male Wistar rats were randomized to receive HES 2 ml.kg-1.hr-1or RL 5 ml. kg-1.hr-1 that underwent 30 minutes of renal ischemia followed by reperfusion. Twelve hours after kidney ischemia, the kidneys were evaluated for histological changes. Serum NGAL levels were obtained at different times of the experimental protocol. RESULTS: Rodents in the HES group had a median (IQR) grade of renal injury 3 (3 to 5) compared to 2 (2 to 4) in the RL group (p=0.03). NGAL levels were not associated with the severity of kidney injury. CONCLUSION: Hydroxyethyl starch administration caused more kidney injury than Ringer's lactate in a non-infectious model of renal hypoperfusion.

Relação entre fatores genéticos envolvidos em vias metabólicas mitocondriais e a doença de Parkinson / Relationship between genetic factors involved in mithocondrial metabolic pathways and Parkinson’s Disease

A doença de Parkinson (DP) é uma das desordens neurodegenerativas mais comuns associada ao envelhecimento, alcançando 2% aos 70 anos. É uma doença caracterizada pela degeneração progressiva de neurônios dopaminérgicos nigrais nos gânglios basais e pela presença de inclusões protéicas citoplasmáticas denominadas corpúsculos e neuritos de Lewy nos neurônios sobreviventes. A etiologia da DP é pouco conhecida, sendo considerada, na maioria dos casos, idiopática. Conhecimentos alcançados nos últimos 15 anos sobre a base genética da DP demonstram, claramente, que os fatores genéticos desempenham um importante papel na etiologia desta desordem. Neste trabalho, rastreamos mutações nos genes que codificam proteínas participantes de vias metabólicas mitocondriais (Parkin, PINK1 e DJ-1) em 136 pacientes brasileiros com manifestação precoce da DP, através do sequenciamento automático e da técnica de MLPA. Avaliamos a presença de variantes de sequência por meio do sequenciamento dos exons 1 a 12 do gene Parkin e dos exons 1 a 8 do gene PINK1. Em Parkin foram identificadas três mutações patogênicas ou potencialmente patogênicas, ambas em heterozigose: p.T240M, p.437L e p.S145N. Em PINK1 não encontramos variantes de ponto patogênicas. Através da técnica de MLPA investigamos alterações de dosagem nos genes Parkin, PINK1 e DJ-1. Identificamos cinco alterações no gene Parkin em quatro pacientes: uma duplicação heterozigota do exon 4 no paciente PAR2256, uma deleção heterozigota do exon 4 no probando PAR2099, uma deleção homozigota do exon 4 na paciente PAR3380 e um probando heterozigoto composto (PAR2396) com duas alterações, uma duplicação do exon 3 e uma deleção dos exons 5 e 6. No gene PINK1 identificamos uma deleção heterozigota do exon 1, que nunca foi descrita na literatura, em um paciente (PAR2083). Não encontramos alteração quantitativa no gene DJ-1. Neste estudo obtivemos uma frequência total de mutações patogênicas (pontuais e de dosagem) nos genes estudados ...

Parkinson's disease (PD) is one of the most common neurodegenerative disorders associated with aging, reaching 2% at age 70. It is a disease characterized by progressive degeneration of nigra dopaminergic neurons in the basal ganglia and the presence of cytoplasmic protein inclusions known as Lewy bodies and neurites in surviving neurons. The etiology of PD is poorly understood, being considered, in most cases, idiopathic. Knowledge achieved in the last 15 years about the genetic basis of PD clearly shows that genetic factors play an important role in the etiology of this disorder. In this study, we screened mutations in genes that encode proteins participating in mitochondrial metabolic pathways (Parkin, PINK1 and DJ-1) in 136 Brazilian patients with early onset PD, through automatic sequencing and MLPA technique. We evaluated the presence of sequence variants by means of sequencing of exons 1 to 12 of Parkin gene and exons 1 to 8 of PINK1 gene. In Parkin gene were identified three pathogenic or potentially pathogenic mutations, both in heterozygous state: p.T240M, p.437L e p.S145N. In PINK1 gene we did not find pathogenic point mutations. Through the MLPA technique we investigated dosage changes in Parkin, PINK1 and DJ-1 genes. We identified five exon rearrangements in Parkin gene in four patients: a heterozygous duplication of exon 4 in patient PAR2256, a heterozygous deletion of exon 4 in proband PAR2099, a homozygous deletion of exon 4 in patient PAR3380 and a compound heterozygote (PAR2396) with two changes, a duplication of exon 3 and a deletion of exons 5 and 6. In PINK1 gene we identified a heterozygous deletion of exon 1, which has never been described in literature, in one patient (PAR2083). We found no quantitative change in DJ-1 gene. In this study, we obtained an overall frequency of pathogenic mutations (sequence and dosage) in the genes studied of 7.3%, being 6.6% in Parkin gene and 0.7% in PINK1 gene

Relación histopatológica de la displasia epitelial con la oncoproteína p53 en la leucoplasia bucal / Histopathological relation of epithelial dysplasia to p53 oncoprotein in oral leukoplakia

La leucoplasia bucal es una lesión precancerosa bien conocida debido a su asociación con la presencia de displasia epitelial y su tendencia a la transformación maligna. Con el fin de eliminar la subjetividad en la determinación de los grados de la displasia epitelial se han utilizado marcadores biológicos, entre ellos, el AcM anti p53. Por ello se propuso evaluar la expresión del AcM anti p53 en los diferentes grados de displasia epitelial en la leucoplasia bucal. Se emplearon las biopsias de 46 pacientes con diagnóstico de leucoplasia bucal, procedentes del Departamento de Patología Bucal de la Facultad de Estomatología de La Habana. Las muestras fueron procesadas por la técnica de inclusión en parafina y coloreadas con la técnica inmunohistoquímica del complejo avidina-biotina-peroxidasa para el AcM p53. Se estudió la correlación entre el patrón de inmunoensayo para p53 y el grado de displasia epitelial. Se evidenció que existe una asociación significativa entre la inmunocoloración de las células basales y suprabasales del epitelio con la oncoproteína p53, en los distintos grados de severidad de la displasia epitelial, lo que pudiera estar relacionado con el incremento progresivo de atipia celular observada. Se concluyó que en las muestras estudiadas existió una relación coincidente del aumento del grado de severidad de la displasia epitelial, con el marcaje de la oncoproteína p53. Estas evidencias sugirieron que el análisis inmunohistoquímico de p53 en conjunto con los parámetros histológicos, principalmente relacionados con el grado de severidad de la displasia epitelial, pudiera ser utilizado para lograr un diagnóstico más certero y contribuir a la prevención del cáncer bucal(AU)

The oral leukoplasia is a well known precancerous injury due to its association with the presence of epithelial dysplasia and its trend to malignant transformation. To eliminate the subjectivity in the determination of the epithelial dysplasia degrees, biological markers have been used among them the AcM.antip53 Thus, authors assessed the expression of AcM antip53 in the different degrees of epithelial dysplasia in the oral leukoplasia. Biopsies from 46 patients diagnosed with oral leukoplasia were used from the Oral Pathology Department of the Stomatology Faculty of La Habana. Samples were processed by the paraffin-inclusion technique and stained with immunohistochemical technique of the avidin-biotin-peroxidase complex for the AcM p53. The correlation between the immunoassay pattern for p53 and the degree of epithelial dysplasia was studied. It was demonstrated that there is a significant association between the immunostain of basal and supra-basal cells of epithelium with the p53 oncoprotein in the different degrees of severity of the epithelial dysplasia, which could be related to the progressive increase of the observed cellular atypia. We concluded that in the study samples there was a coincident relation of the increase in the degree of severity of the epithelial dysplasia, with the marking of the p53 oncoprotein. These evidences suggested that the immunohistochemical analysis of p53 overall with the histological parameters mainly those related to the degree of severity of the epithelial dysplasia could be used to made a more accurate diagnosis and to contribute to prevention of oral cancer(AU)

O uso dos biomarcadores p16 e Ki-67 em citologia cérvico-vaginal: revisão de estudos / The use of biomarkers p16 and Ki-67 in cervix-vaginal cytology: studies review

O Papilomavirus humano- HPV possui diversas variáveis, algumas delas, classificadas como de alto risco, estão envolvidas na etiologia das lesões pré-neoplásicas e neoplásicas do colo uterino. Isto se dá pela integração das oncoproteínas virais E6 e E7 aoDNA da célula infectada, desestabilizando seu ciclo celular. Os biomarcadores moleculares possuem um importante papel preditivo nas doenças. Dentre muitos pode-se destacar a proteína Ki-67, um marcador de proliferação celular e a proteína supressora tumoral p16, que tem sido muito estudada em casos de lesões de colo uterino por sua possível função como marcadora prognóstica. Oobjetivo deste artigo é comparar os resultados dos estudos quanto à associação da expressão dos biomarcadores em diferentes diagnósticos de citologia cérvico-vaginal .

The human papillomavirus-HPV has many variables, and some of them are classified as high risk. HPV are involved in the aetiology of pre-neoplastic and neoplastic lesions of the cervix. This is due to integration of viral oncoproteins E6 and E7 DNA of the infected cell disrupting the cell cycle. The molecular biomarkers have an important predictive role in diseases. The Ki-67 protein is used as marker of cell proliferation, and the tumor suppressor p16 protein has been studied in cases of cervix lesons forits possible role as a prognostic marker. The aim of this paper is to compare the results of studies regarding the association of expression of biomarkers in different diagnoses of cervicovaginal cytology.

Prevenção do câncer cervical: associação da citologia oncótica a novas técnicas de biologia molecular na detecção do papilomavírus humano (HPV) / Cervical cancer prevention: association of new techniques of molecular biology with the oncotic cytology in detection of human papillomavirus (HPV)

O câncer do colo uterino é conhecido como uma das causas mais frequentes de óbito na população feminina em todo o mundo. A infecção persistente por papilomavírus humano (HPV) é o principal fator de risco para o câncer cervical e suas lesões precursoras. Objetivo: avaliar os métodos diagnósticos do câncer cervical: citologia oncótica, DNA do HPV pela PCR, detecção do RNAm das proteínas E6 e E7 dos HPVs de alto risco, para acrescentar novos marcadores na detecção do HPV em amostras com citologia alterada. Métodos: foram avaliados os resultados da citologia oncótica de3.000 pacientes, atendidas no Laboratório Vital, Nonoai - RS, de março de 2009 a janeiro de 2010, classificando-as conforme a faixa etária e codificação de Bethesda, 2001. Foram selecionados dois grupos: o grupo A incluiu pacientes com citologia prévia alterada e o grupo B, pacientes com citologia sem anormalidades. Foram coletadas 47 amostras, 22 do grupo A e 25 do grupo B. Três amostras do grupo B apresentaram inibidores da PCR e foram excluídas.A análise dos dados considerou 22 amostras em cada grupo. A detecção do HPV foi feita pela reação em cadeia da polimerase (PCR) utilizando-se os primers consenso MY9/11 e GP5+/6+. O RNAm das proteínas E6 e E7 foi detectado pelo método Real-Time NASBA. Resultados: nas amostras do grupo A, houve detecção do DNA/HPV pela PCR em 14 (64%) amostras, e RNAm das proteínas E6 e E7 do HPV em seis (27%) amostras. Todas as 22 amostras do grupoB foram negativas nos métodos moleculares. Conclusão: neste estudo, a citologia prévia alterada associada a testes moleculares indica a necessidade de monitoramento ou intervenção terapêutica das pacientes. Assim, conclui-se que a citologia oncótica associada à detecção do DNA do HPV pela PCR e à expressão das oncoproteínas E6 e E7 é a alternativa para identificar precocemente pacientes com elevado risco de desenvolver o câncer cervical.

Worldwilde, the cervical cancer is known as one of the most frequent cause of death in female population. Persistent infection with oncogenic human papillomavirus (HPV) is the main risk factor for cervical cancer and its precursor lesions. Objective: to evaluate the diagnostic methods of cervical cancer: oncotic cytology, HPV DNA by PCR, detection of mRNA E6 / E7 proteins of high-risk HPV, to add new markers in the detection of HPV.Methods: were evaluated 3,000 results of oncotic cytology from patients referred to Vital Laboratory, Nonoai- RS, Brazil, from March 2009 to January2010. The results were grouped according age and Bethesda classification, 2001. Group A included patients with previous altered cytology and GroupB patients without abnormalities in cytology. To molecular tests were collected 47 samples, 22 from group A and 25 from group B. Three samples from group B presented PCR inhibitors and were excluded. The detection of HPV was made by polymerase chain reaction (PCR) using the consensus primers MY9/11 and GP5 +/6 +. The mRNA E6 / E7 proteins were detected by real-time NASBA. Results: in samples of group A, DNA/HPV was detected in 14(64%) samples, and mRNA E6 / E7 proteins of HPV was detected in 6 (27%) samples. All 22 samples of group B were negative to molecular methods.Conclusion: in this study, the previous altered cytology associated with molecular methods indicates the need for monitoring or therapeutic intervention of patients. The oncotic cytology associated with the detection of HPV DNA by PCR and the expression of oncoproteins E6 / E7 are alternatives to identify early lesions in patients with high risk of developing cervical cancer.

High prevalence of thyroid disorders in relatives of patients with familial papillary thyroid cancer / Elevada prevalencia de alteraciones tiroideas en familiares de pacientes con diagnóstico de carcinoma papilar familiar

In the familial form of papillary thyroid cancer (PTC), two or more members of the same family have to be affected with PTC. Prevalence is around 5% of all PTC. We performed a clinical analysis in 79 relatives of 16 patients of 7 unrelated kindred with the diagnosis of familial papillary thyroid carcinoma (FPTC). The results were compared with a control group. Thyroid palpation and TSH and TPO-Ab assessment was carried out in the relatives without a diagnosed PTC. Additionally, molecular analysis was performed in the sixteen affected patients. Clinical screening of the 79 family members showed the presence of goiter in 22/79 (29 %). This frequency was much higher than that observed in the control group (8.7%), p < 0.001. Hypothyroidism was found in 4 of the relatives (5%) vs. 2.5% observed in the control group, p < 0.01, and anti-thyroid antibodies (TPO-Ab) were positive in 14% of the relative's group vs. 10 % in the control group, (p = NS). In the molecular analysis, only a protooncogene TRK rearrangement was observed in family # 6. In conclusion, we found a higher incidence of goiter and hypothyroidism in the relatives of patients with FPTC. Nevertheless, TPO-Ab frequency was not different. No molecular abnormalities were indicative of a specific pattern in this subset of patients with FPTC.

En la forma familiar del carcinoma papilar de tiroides (CPT), dos o más miembros de la misma familia deben presentar CPT. Esta entidad ocurre en aproximadamente el 5% de todos los CPT. En este estudio, realizamos una evaluación de 79 familiares de 16 pacientes con diagnóstico de carcinoma papilar familiar (CPF) provenientes de 7 familias diferentes. Los resultados se compararon con los hallados en un grupo control. Se realizó palpación tiroidea y medición de TSH y anticuerpos anti-tiroperoxidasa (TPO-Ab) en todos los familiares. Además, se llevó a cabo el análisis molecular en los 16 sujetos que presentaban el diagnóstico de CPF. La evaluación de los 79 familiares de estos pacientes demostró la presencia de bocio en 22/79 (29%). Esta frecuencia fue mucho mayor que la observada en el grupo control (8.7%), p < 0.001. Se diagnosticó hipotirodismo en 4 familiares (5%) vs. 2.5%, observado en el grupo control, p < 0.01, y los TPO-Ab fueron positivos en 14% de los familiares vs. 10% del grupo control, (p = ns). En el análisis molecular, solamente se halló un rearreglo del protoncogen TRK en una de las 7 familias con CPF. En conclusión, hallamos una elevada prevalencia de bocio e hipotiroidismo en los familiares de pacientes con CPT. Sin embargo, la frecuencia de autoinmunidad no fue diferente. No se hallaron alteraciones moleculares distintivas en estos pacientes con CPF.

Caracterização de metaloproteinases de matriz e reck em queratinócitos primários que expressam oncoproteínas do papilomavírus humano (HPV) / Characterization of matrix metalloproteinases and reck in primary keratinocytes that express human papillomavirus (HPV) oncoproteins

Os tumores da cérvice-uterina, que representam uma das principais doenças ginecológicas em mulheres na idade reprodutiva em todo o mundo, estão etiologicamente associados com a infecção pelo papilomavírus humano (HPV). A progressão de uma lesão intraepitelial escamosa de baixo-grau (LSIL) a um carcinoma invasivo de cérvix uterina está acompanhada da degradação da matriz extracelular (MEC) devido à ação progressiva das metaloproteinases de matriz (MMP-2, MMP-9 e MMP-14) no processo de invasão e metástase. Entretanto, o balanço entre as MMPs e seus reguladores como RECK e TIMPs é necessário para controlar esta invasão. O objetivo deste projeto consiste em avaliar a atividade e a expressão das metaloproteinases 2, 9, e 14, e caracterizar a expressão do gene supressor de metástase RECK e do inibidor tecidual de metaloproteinases (TIMP-2), em modelo de queratinócitos humanos infectados com retrovírus recombinantes que expressam os oncogenes E6 e/ou E7 de HPV 16, em culturas cultivadas em monocamada e organotípicas. Para isso, utilizamos ensaios de real-time PCR, zimografia, western blot, imunocitoquímica, ensaio de ELISA e imunohistoquímica. Em culturas em monocamada observamos que as células que expressam as oncoproteínas E6E7 de HPV16 apresentaram menores níveis protéicos de RECK e TIMP-2 em relação ao controle pXLSN. Quando analisamos as culturas organotípicas, também observamos esta diminuição dos níveis de RNAm e protéicos de RECK em rafts que expressam E6E7, acompanhado pelo aumento da atividade de MMP-9, em relação ao controle. Também observamos que o tratamento das culturas com a citocina TNF aumenta a expressão gênica, protéica e atividade de MMP-9 em todas as linhagens analisadas. Além disso, os oncogenes E6 e/ou E7 não afetam a expressão e/ou atividade de MMP-2, MT1-MMP. Nossos dados demonstraram que a expressão das oncoproteínas E6E7 de HPV16 estão relacionadas com o desequilíbrio entre MMPS e seus inibidores, sugerindo que em uma fase pré-invasiva do...

Cervical cancer is etiologically associated with to high-risk human papillomavirus (HPV) infection. It has been observed that matrix metalloproteinases (MMPs) -2, -9, and MT1-MMP are required for basement membrane degradation during cervical carcinoma progression. Moreover, a counterbalancing among MMPs and their regulators, such as TIMPs and RECK, is necessary to modulate invasion. In order to study the effect of HPV oncogenes on MMPs expression, primary human keratinocytes (PHKs) were infected with recombinant retroviruses expressing wild-type HPV16 E6 and/or E7 oncogenes and were used to seed monolayers and organotypic cultures. Quantitative real-time PCR (Q-PCR), western blot, zimography, immunocitochemistry, ELISA assay and immunohistochemistry were used to determine the expression level and activity of MMP-2, MMP-9, MT1-MMP and their inhibitors RECK and TIMP-2. We observed that cultures expressing E6E7 presented lower RECK and TIMP-2 protein levels than control keratinocytes. In addition, rafts cultures presented the same lower RECK levels additionally presenting higher MMP-9 activity than control. Furthermore, we observed that expression of E6 and/or E7 proteins do not affect MMP-2 and MT1-MMP protein levels and/or activity. We also observed that TNF treatment enhance the MMP-9 gene and protein expression and activity in all studied cell lines. Taken together, our results demonstrate that HPV16E6E7 expression is related with the unbalance between MMPs and their inhibitors, suggesting that in the initial steps of HPV-related cervical disease, not only MMPs but also RECK and TIMP-2 are critical for tumor progression.

The performance of semi-quantitative differential PCR is similar to that of real-time PCR for the detection of the MYCN gene in neuroblastomas

Amplification of the MYCN gene in neuroblastomas is a potent biological marker of highly aggressive tumors, which are invariably fatal unless sound clinical management is applied. To determine the usefulness of semi-quantitative differential PCR (SQ-PCR) for accurate quantification of MYCN gene copy number, we evaluated the analytical performance of this method by comparing the results obtained with it for 101 tumor samples of neuroblastoma to that obtained by absolute and relative real-time PCR. Similar results were obtained for 100 (99 percent) samples, no significant difference was detected between the median log10 MYCN copy number (1.53 by SQ-PCR versus 1.55 by absolute real-time PCR), and the results of the two assays correlated closely (r = 0.8, Pearson correlation; P < 0.001). In the comparison of SQ-PCR and relative real-time PCR, SQ-PCR versus relative real-time PCR concordant results were found in 100 (99 percent) samples, no significant difference was found in median log10 MYCN copy number (1.53 by SQ-PCR versus 1.27 by relative real-time PCR), and the results of the two assays correlated closely (r = 0.8, Pearson correlation; P < 0.001). These findings indicate that the performance of SQ-PCR was comparable to that of real-time PCR for the amplification and quantification of MYCN copy number. Thus, SQ-PCR can be reliably used as an alternative assay in laboratories without facilities for real-time PCR.